Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?  by Remuzzi, Giuseppe & Bertani, Tullio
Kidney International, Vol. 38 (1990), pp. 384—394
EDITORIAL REVIEW
Is glomeruloscierosis a consequence of altered glomerular
permeability to macromolecules?
Background
Focal and segmental glomerulosclerosis (FSG) can be re-
garded as a common pathological counterpart of various dis-
eases of the kidney associated with altered glomerular perme-
ability to macromolecules that results in abnormal urinary
protein excretion. The human diseases include steroid-resistant
nephrotic syndrome, some primary glomerulonephritis, vascu-
lar diseases of the kidney, reflux nephropathy and the recently
identified nephropathy associated with acquired immunodefi-
ciency syndrome [1]. Several theories have been proposed to
clarify the pathogenesis of focal and segmental glomerulosciero-
sis which is associated with progressive deterioration of renal
function. These include changes in glomerular hemodynamics,
with increased glomerular pressure and flow 121, activation of
coagulation processes in glomerular microvessels [3], lipid
deposition [4] and glomerular hypertrophy [5].
There is evidence for and against the role of each of these
mechanisms as responsible for glomerulosclerosis, but so far no
definite proof is available that any one of them fully explains the
process of glomerular obsolescence.
In the present review the possibility of abnormal transit of
plasma proteins through the glomerular capillary membrane
being the key factor in glomeruloscierosis will be addressed.
This view is based on the assumption that each of the mecha-
nisms considered so far in the various experimental settings
alters glomerular permselectivity, thus setting in motion a
cascade of events ultimately leading to glomerulosclerosis.
Experimental models of altered glomerular permselective
properties and evidence that proteinuria correlates with
subsequent glomerulosclerosis
Renal mass ablation
When the number of nephrons is reduced in the rat by
surgical ablation or infarction, glomerular capillary pressure
and flow increase in the remaining nephrons [6, 7]. As a
consequence the glomerular filtration rate (GFR) of intact
glomeruli rises as a compensatory mechanism to keep the
kidney functioning after the reduction of renal mass [7]. How-
ever, the sustained increase in glomerular capillary pressure
and flow is eventually associated with glomerular injury, as
documented by vacuolization of epithelial cells and foot process
fusion [8]. In a few months mesangial matrix expands and
endothelial cells become detached from basement membrane
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(GBM) in focal areas; these findings precede a process of
progressive sclerosis of the glomerular tuft that leads to dete-
rioration of renal function [9].
Of note is the fact that urinary protein excretion increases in
this model—as a consequence of loss of permselective proper-
ties of the glomerular barrier—very soon after surgery or
infarction and well before glomeruloselerosis develops [81. The
characteristics of altered glomerular selectivity in the remnant
kidney have been further investigated by Olson et a! [8]
studying the fractional clearance of neutral dextrans. These
authors found increased fractional clearance values for dcx-
trans larger than 38 A, but not in the range of 20 to 38 A
molecular radii. This is in keeping with another study [10]
showing in the same model a partial loss of the size-selective
properties. Besides size-selectivity, charge-selectivity may be
altered in the remnant kidney as documented by a defect in the
ability to restrict negatively charged macromolecules [81.
The loss of charge-selectivity in remnant kidney may also be
explained by an increased number of larger pores which mini-
mize the effect of charge on the passage of macromolecules.
The mechanism of the evolution of renal disease to glomerulo-
sclerosis proposed by studies on the ablation model is of great
interest as it also applies to other models of renal injury in
which the glomerular capillary pressure increases not because
of renal mass reduction, but as consequence of diffuse injury to
the whole nephron population. This is, for instance, the case of
post-salt [11] and mineral corticoid-induced hypertension in the
rat [12, 13].
In all the mentioned experimental models of glomerulosclero-
sis, dietary or pharmacological manipulations which limit the
evolution of the disease to glomeruloscierosis also interfere
with glomerular barrier permselective properties, as docu-
mented by a reduction of urinary protein excretion. Thus, low
protein diet or the use of angiotensin converting enzyme
inhibitors, enalapril or captopril, protects animals against renal
disease progression [8, 14, 15]. This fact, besides being associ-
ated with a reduction in the number of sclerotic glomeruli, is
also consistently associated with a reduction in proteinuria [8,
14, 15]. A possible interpretation of these findings is that these
maneuvers may restore permselective properties of glomerular
capillaries.
However, whether proteinuria is simply a marker of the
extent of glomerular damage or may itself promote the subse-
quent evolution of the disease to sclero-hyalinosis of the
glomerular structure has not been clarified so far. Findings of
nearly normal glomerular epithelial cell structure and function
in rats with remnant kidneys three weeks after the ablation
procedure, when animals are already proteinuric, suggest that
proteinuria precedes the structural glomerular epithelial cell
changes detectable by electron microscopy [16], Changes in
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glomerular epithelial cell structure which follow a few weeks of
heavy proteinuria can therefore be regarded as the consequence
of increased uptake of abnormally filtered plasma proteins.
Diabetes me/litus
Both in animals and humans, diabetes mellitus is associated
with elevated GFR and renal plasma flow in the early phases of
the disease [17—231. Several explanations have been put forward
for the early hyperfiltration in experimental diabetes, including
hyperglycemia [24, 25], loss of sensitivity of the tubuloglomer-
ular feedback mechanism [25, 26], and possibly humoral agents
such as vasodilatory prostaglandins [27, 28] and atrial natri-
uretic factor [29].
Independently of the mechanism(s) responsible for hyperfil-
tration, rats with long-standing moderate hyperglycemia de-
velop focal and segmental glomerulosclerosis, always preceded
by proteinuria [22, 23]. Because glomerular capillary pressure is
increased in these animals and maneuvers that limit glomerular
capillary hypertension also limit the progressive renal disease of
diabetic rats, it was assumed that the alterations in glomerular
membrane permeability were the consequence of changes in
glomerular hemodynamics [22, 23]. However, increased gb-
merular capillary pressure is not a requisite for the development
of glomerular injury in experimental diabetes, as demonstrated
by severely hyperglycemic diabetic rats not given supplemental
insulin [30, 31] that have reduced single nephron glomerular
filtration rate (SNGFR) and capillary hydraulic pressure, de-
spite persistent proteinuria.
The relation between urinary protein excretion and glomer-
ular injury has been explored in another strain of rats, the
BioBreedingIWorcester (BB/W) rats, which develop spontane-
ous autoimmune insulitis, insulinopenia and hyperglycemia,
mimicking the syndrome of type I diabetes in humans [32, 33].
These rats develop renal hypertrophy [34, 351, progressive
thickening of GBM, which is greater in rats with poor glycemic
control than in rats with moderate hyperglycemia. However,
unlike the majority of insulin-dependent diabetes mellitus
(IDDM) patients and streptozotocin-induced diabetic rats with
severe hyperglycemia, kidneys of the BBIW diabetic rats do not
have mesangial expansion [34, 36]. In this strain of rats protein-
uria occurs and correlates with the degree of glycemic control
and GBM widening [36]. Of note, whole-animal studies of this
particular strain of diabetic rats have reported no [35] or
moderate [34] glomerular hyperfiltration, whether GFR was
factored or not for kidney weight. However, direct measure-
ments of the determinants of SNGFR in diabetic BB!W rats
have not been performed, making difficult the comparison with
the glomerular hemodynamic changes reported in the strepto-
zotocin diabetes.
Early hyperfiltration followed by gbomerular structural injury
is not peculiar to streptozotocin diabetic rats but is also a
feature of human diabetes mellitus [17—19]. Moreover, 30% of
patients with insulin-dependent diabetes develop microalbumin-
uria in the early phase of the disease and subsequently overt
nephropathy [17, 37, 38]. It is generally believed that early
hyperfiltration is a marker of progression of the disease to overt
diabetic nephropathy thus raising the question of the relation-
ship between hemodynamic changes—and possibly the increase
in glomerular capillary pressure—and the subsequent develop-
ment of glomerulosclerosis [17].
At variance with abundance of data in experimental animals,
there are a few studies correlating urinary protein excretion
with the degree of glomerular injury in human diabetes mellitus.
It is known that in man the development of microalbuminuria is
a reliable marker of the evolution of the disease to overt
nephropathy [39, 40], while patients with diabetes and normal
urinary albumin do not develop renal disease [41, 42]. Of note,
very slight elevation of blood pressure occurs in insulin depen-
dent diabetics with normal urinary albumin excretion while high
blood pressure is commonly observed in diabetics with heavy
proteinuria [43]. Thus, when mean blood pressure was plotted
against urinary albumin excretion rate in patients with insulin
dependent diabetes with or without diabetic nephropathy and,
within the latter group, with incipient or overt nephropathy a
highly significant correlation was found [43]. Thus, it is not
surprising that when diabetic patients develop proteinuria in a
nephrotic range renal function rapidly deteriorates to end-stage
renal failure [44, 45]. This has been carefully documented by
Goldstein and Massry [46], who noted that in a large population
of diabetics with nephrotic proteinuria end-stage renal failure
rose in less than three years. The hypothesis of a beneficial
effect of antihypertensive treatment on the progression of renal
disease in diabetic patients with established nephropathy was
recently confirmed by Parving and coworkers [47]. These
authors demonstrated that the institution of an aggressive
antihypertensive treatment, with reduction in mean arterial
pressure from approximately 110 to 100 mm Hg, was able to
reduce the rate of decline in the GFR on average from 0.9 to 0.2
mI/mm/month and albuminuria from about 1000 to 500 tgImin.
Of note, the favorable effect of antihypertensive therapy on
progression of the renal disease is always associated with a
marked reduction of urinary protein excretion. This and others
studies [48, 49] do not allow definitive conclusions, but are
consistent with the possibility that antihypertensive therapy in
this setting may retard the progression of diabetic nephropathy
by an effect mediated by reduction in proteinuria. It is, how-
ever, of great interest that both in diabetic animals and humans
maneuvers that retard glomerular structural injury also reduce
proteinuria. Angiotensin converting enzyme inhibitors, that
lower capillary hydraulic pressure and reduce glomerular dam-
age in diabetic rats [23, 50] and slow the decline in renal
function in human diabetic nephropathy [51, 52], also reduce
urinary protein excretion rate. These findings would suggest
that in diabetes, as in most other forms of glomerulosclerosis,
abnormal glomerular permeability to proteins is a determinant
of progressive renal disease.
This interpretation is consistent with the observation that in
rats with streptozotocin-induced diabetes high-protein diet
markedly increases urinary albumin excretion and is associated
with a high incidence of glomerular lesions, while restriction of
dietary proteins prevented both albuminuria and glomerulo-
sclerosis [22]. Further studies [23] showed that chronic treat-
ment with the angiotensin converting enzyme inhibitor, enala-
pril, had a protective effect similar to that of dietary protein
restriction. In sharp contrast with the nearly exponential pro-
gression of albuminuria in untreated diabetic rats, enalapril
treated animals have almost normally preserved glomerular
selective properties as well as minimal glomerular structural
changes, indistinguishable from those of control rats of similar
age.
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That glomerulosclerosis correlates with urinary protein ex-
cretion in diabetes has been very convincingly documented by
the recent study of Anderson et a! [50]. These authors studied
the short- and long-term effects of antihypertensive therapy in
experimental diabetes and found that compared to untreated
diabetic animals which had albuminuria and marked glomeru-
loscierosis, triple antihypertensive therapy delayed but not
prevented albuminuria. Triple therapy also reduced glomerulo-
sclerosis but was less effective than captopril. In the same
setting captopril reduced albuminuria to below that of control
rats of the same age. Of great interest was the finding that
diabetic rats given captopril also had a percentage of sclerotic
glomeruli lower than age-matched control rats.
Aging
In certain strains of rats, aging is associated with progressive
proteinuria and glomeruloscierosis that subsequently lead to
renal insufficiency [53—55]. If the animals are fed a high-protein
diet both proteinuria and renal lesions are aggravated [56, 57].
Food restriction or reduction of dietary protein reduces both
proteinuria and the age-related renal disease [56, 58—60]. We
have recently evaluated the time course of urinary protein
excretion in aging rats exposed to diet with protein content
ranging from 6% to 35% [61]. A high-protein diet, which is
associated with a higher percentage of glomerular sclerotic
lesions than the standard diet, was also associated with a
significant increase in urinary protein excretion. By contrast
low-protein diet, which protected animals from the develop-
ment of late glomeruloscierosis, also reduced the amount of
urinary proteins. At the onset of proteinuria no renal structural
abnormalities were detected at the histological examination of
the kidney in the various animal groups. A remarkable finding
of this study was that three out of ten rats on standard diet (20%
protein) that did not develop proteinuria, were also free of renal
lesions after up to 20 months of observation. This study also
addressed the important issue of whether the injurious effect of
proteinuria is 'dose dependent' or is a 'threshold phenomenon'.
Actually, for urinary protein excretion values lower than 60
mg/day no development of glomeruloscierosis was observed
during the two months of observation, while rats with urinary
protein excretion exceeding 100 mg/day for the same period had
a degree of glomeruloscierosis proportional to the severity of
proteinuria. That glomerulosclerosis correlated with the sever-
ity of proteinuria for values of urinary proteins above 100
mg/day in the rat has also been observed in other models [62,
63]. This and other similar studies [53, 54] indicate that protein-
uria precedes the development of glomerular sclerotic lesions in
aging rats. A potentially important finding of this study is the
highly significant positive correlation between the degree of
glomerular sclerotic lesions and the tubulointerstitial damage,
that is, tubular casts and dilatation, atrophy and interstitial
mononuclear cell infiltrates [61]. The association between gb-
merulosclerosis and tubulointerstitial lesions has been reported
by others [64] in aging rats, and probably applies to other
models of proteinuria and renal disease progression in the rat,
as documented in the remnant kidney model and in experimen-
tal nephrosis [65—67]. In other studies [62, 68] a particular strain
of rats, Munich-Wistar rats (MWF/Ztm), originally selected for
their large number of superficial glomeruli, was used to corre-
late abnormal urinary protein excretion with glomerular hemo-
dynamics and glomerular lesions. Urinary protein excretion in
these rats is higher than in other strains. Moreover, the males
had significantly higher urinary protein excretion than females
at seven weeks of age, with a progressive increase that reached
near 300 mg/24 hr at week 21, while females of the same age had
some 20 to 30 mg124 hr proteinuria [68]. Because in this model
the glomerular damage develops spontaneously, unlike in rats
undergoing renal mass reduction or given renal toxins, this may
be regarded as an ideal model to study the mechanisms under-
lying renal disease progression. We have recently addressed
whether changes in glomerular hemodynamics might explain
the abnormal glomerular permeability to proteins of male
MWF/Ztm rats. The results showed a 60% higher SNGFR in
males than females, single nephron gbomerular plasma flow
(QA) tended to be higher although not significantly so [68], but
intraglomerular capillary pressure was comparable in males and
females. Although glomerular hypertension was not docu-
mented in this model, enalapril ameliorated the progression of
glomerular injury by significantly reducing proteinuria and
glomerubosclerosis [62]. The beneficial effect of enalapril was
associated with a significant reduction of systemic blood pres-
sure. Micropuncture studies revealed that enalapril also re-
duced glomerular capillary hydraulic pressure to lower than
normal values by reducing afferent and efferent arteriolar
resistance [62]. It appears unlikely that the reduction in glomer-
ular capillary pressure was responsible for protecting against
proteinuria in this model since untreated male and female
MWF/ztm rats had comparable glomerular capillary pressure at
18 to 20 weeks of age, but glomerular damage developed only in
males. In the above-mentioned study we also documented that
enalapril ameliorated glomerular size-selective barrier in this
model, as indicated by a significant decrease in ifitration of
neutral dextran macromolecules of graded sizes with effective
molecular radius ranging from 26 to 64 A [62]. The theoretical
analysis of experimental data [62] documented that converting
enzyme (CE) inhibition uniformly reduced the radius of all
membrane pores and that this reduction was predominant for
pores having radii around the mean. These data suggest that
enalapril exerts a direct beneficial effect on intrinsic membrane
permeability properties. The fact that the resulting reduction in
urinary protein excretion was associated with a marked protec-
tion against the development of glomerular sclerotic lesions [62]
would indicate that the two phenomena may be causally re-
lated.
Adriamycin and puromycin nephrosis
Adriamycin (ADR) and aminonucleoside of puromycin (PA)
both induce changes in glomerular capillary selective properties
in the rat, with proteinuria, overt nephrotic syndrome, and
morphological features reminiscent of human "minimal
change" nephropathy [69—74]. Animals given ADR or PA
develop glomerulosclerosis within a few months [75—77]. As in
the other models of chronic proteinuria discussed above, most
of these studies documented a close relationship between
tubulointerstitial changes [67, 75] and the development of FSG,
and clarified that interstitial changes and casts always preceded
the onset of FSG [78]. Similarly to ADR, in the rat PA induces
a nephrotic syndrome with ultrastructural findings of epithelial
cell damage which include foot process fusion. The disease
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manifests with progressive proteinuria associated with various
degrees of tubulointerstitial changes and evolution to glomeru-
loscierosis [66].
Measurements of intraglomerular capillary pressure in ADR
or PA nephrosis have led to conflicting results so far. Fogo et al
[79] have measured normal glomerular capillary hydraulic pres-
sure during the course of ADR nephrosis, while O'Donnell et al
[80] and more recently Scholey Ct al [67] measured an increased
intraglomerular capillary pressure in ADR treated compared to
non-treated animals. In ADR nephrosis Scholey et al [67]
demonstrated that enalapril preserved GFR compared to the
untreated animals, without beneficial effect on proteinuria and
glomeruloscierosis. In another recent study Beukers et a! [81]
confirmed that ADR animals treated with captopril were not
protected from proteinuria and glomerulosclerosis.
In PA nephrosis Fogo et a! [79] found normal intraglomerular
capillary pressure in the early phase of the disease. Of interest
in this study is that enalapril reduced the extension of glomer-
uloscierosis despite the lack of glomerular hypertension. This
study is challenged by the work of Anderson et al [631, who
found that glomerular capillary pressure in the early phase of
PA nephrosis is normal but it increases later in the course of the
disease. In the latter phase the use of an angiotensin converting
enzyme inhibitor lessened both abnormal urinary protein excre-
tion and glomerulosclerosis, once again raising the possibility
that the two phenomena are interdependent.
Overloadproteinuria
Repeated injection of bovine serum albumin in the rat in-
creases glomerular barrier permeability properties, inducing
proteinuria as the result of the formation of large hypothetical
pores through the glomerular capillary [82—86]. Efforts to doc-
ument immune aggregates in the glomeruli of protein injected
animals have given negative results so far, but this maneuver
may induce the formation of antibodies to bovine serum albu-
min so the theoretical possibility that proteinuna in this model
results from an immune reaction cannot be excluded. An
alternative way to achieve overload proteinuria is the liver
hyperplasia that follows rat pituitary tumor transplantation [871.
This raises the blood albumin level through production of
adrenocorticotropic and growth hormone secretion. In turn,
hyperalbuminemia promotes proteinuria and, a few weeks later,
tubulointerstitial lesions and glomerular lesions develop, similar
to those of ADR nephrosis and aging rats. Such changes are
preceded by extensive epithelial cell abnormalities reminiscent
of those found in ADR or PA nephrosis. Findings of normoal-
buminemia, normalization of urinary protein excretion and
reduction of tubulointerstitial changes and glomerulosclerosis
after ablation of the tumor suggest a pathogenetic role of
proteinuna in the development of interstitial and glomerular
lesions. Whether glomerular structural damage is hemodynam-
ically mediated or is secondary to microvascular thrombosis or
tubulointerstitial inflammation cannot be established at the
present moment. So far, no studies have been made on glomer-
ular hemodynamics or permeability properties by dextran siev-
ing curves in this model.
Analysis of the experimental data that apparently conflict with
the hypothesis that glomerulosclerosis is a consequence of
altered glomerular permselective properties
The different models of proteinuria so far analyzed show a
clear association between changes in the glomerular permselec-
tive properties and glomerulosclerosis. However, in some other
instances such a relationship appears less evident. A typical
example is possibly the Heymann nephritis in which the series
of published papers would indicate that glomeruloscierosis does
not occur despite immune deposits on the glomerular capillary
wall and proteinuria [88—92]. A critical review of the studies
published during the past 15 years, however, shows that this
opinion is essentially based on short-term studies which do not
exceed three months. Moreover, proteinuria is generally in a
range of 50 to 70 mg/day which admittedly is not high enough to
promote glomerular sclerotic lesions in other models [88—93]. In
the few studies showing a proteinuria in excess of 100 mg/day
the animals were only followed for two to three weeks [90, 91],
again making it difficult to derive any definitive conclusion. This
period is too short to induce FSG, as documented in other
models of proteinuria in which even four to five weeks of severe
proteinuria failed to induce FSG [69, 71].
More recently, Harris and coworkers [94] have found that
uninephrectomized rats injected with aminonucleoside of puro-
mycin have nephrotic syndrome, hypercholesterolemia and
focal sclerosis. Treatment with lovestatin, which reduces serum
cholesterol, was followed by a lessening of glomerular sclerotic
changes without reducing urinary protein excretion. They sug-
gested that hypercholesterolemia might play an important role
in the progression of glomerular diseases independently of the
degree of proteinuria. However, a careful analysis of these data
demonstrates that treated animals with less severe glomerular
changes, still had more than 70% of glomeruli affected by
moderate or severe sclerotic changes, thus supporting the view
that besides hypercholesterolemia proteinuria has a major im-
pact on glomerulosclerosis [94]. This conclusion is also consis-
tent with the recent report of Sanfelice and coworkers [951, who
found that analbuminemic diabetic rats had much higher cho-
lesterol levels than diabetic SD animals. Despite the marked
hypercholesterolemia, analbuminemic rats developed less gb-
meruloscierosis than hypercholesterolemic diabetic SD rats.
Again, diabetic SD rats with more severe sclerotic changes had
a much higher urinary protein excretion (340 45 vs. 131
19.5 mg/day) than hypercholesterolemic diabetic animals.
Reactive mechanisms triggered by an increased protein traffic
across the glomerular capillary that may favor the process of
glomerulosclerosis
Mesangial cell overload
It has been speculated that increased flux of macromolecules
through the mesangium may lead to "mesangia! cell overload",
mesangial injury and proliferation, which in turn can induce
overproduction of mesangial matrix and eventually lead to
glomerubosclerosis [96, 97]. Actually mesangia! cells in culture
have been found to produce mesangial matrix constituents that
include collagen types IV and V, laminin and fibronectin [98].
The possibility that abnormal permeability of glomerular bar-
rier, resulting in enhanced mesangial "traffic" of macromol-
ecules, activates mesangia! cells and leads to glomerulosclero-
388 Remuzzi and Bertani: Glomerulosclerosis
sis is supported by the observation that the development of
focal glomeruloscierosis in rats after unilateral nephrectomy
[961, as well as in PA nephrosis [97] is related to areas of
increased accumulation of a colloidal carbon tracer, so that
glomeruli with focal sclerosis contained significantly more
carbon than normal glomeruli. It is of interest that a low-protein
diet reduced mesangial accumulation of ferritin as well as
structural abnormalities in the remnant kidney model 181.
Whether the increased flux of macromolecules simply results
from changes in glomerular barrier permselectivity [99], or is
the consequence of a delayed mesangial clearance of macro-
molecules has not been fully clarified. However, the fact that
alterations in glomerular pemeability and proteinuria always
lead to mesangial accumulation of macromolecules has been
challenged by another study showing that, despite comparable
degree of proteinuria, only in PA but not ADR nephrosis or
Heymann nephritis, an increased glomerular uptake of aggre-
gated IgG was demonstrated [100]. This phenomenon was
inhibited by saralasin, suggesting that angiotensin II mediated
mesangial uptake of macromolecules in PA nephrosis. In more
general terms, the notion that an increased flux of macromol-
ecules through the mesangial area stimulates mesangial cells to
proliferate and generates mesangial matrix components has
received great emphasis over the last few years. The definitive
evidence that this is indeed the case is not available, and factors
modulating mesangial cell function in the various models re-
main ill defined. Certainly more studies are needed to address
this important point in order to clarify whether the abnormal
traffic of macromolecules can contribute to the process of
glomerular obsolescence via mesangial cell activation.
Glomerular epithelial cell damage
All the experimental models of chronic proteinuria described
above, as well as their human counterparts (that is, minimal
change glomerulopathy, focal and segmental sclerosis, diabetic
nephropathy, and nephropathy associated with acquired immu-
nodeficiency syndrome) have in common ultrastructural find-
ings of severe epithelial cell damage that include vacuolization,
fusion of foot processes and focal detachment of epithelial cells
from the underlying basement membrane [I], All these changes
appear to be the consequence of chronic proteinuria. Schwartz,
Bidani and Lewis [1011 investigated the relationship between
chronic proteinuria and epithelial cell structure and function in
rats made proteinuric for up to eight weeks by daily injection of
homologous albumin. They documented protein reabsorption
droplets and vacuoles, and cytoplasmic hypertrophy but could
not detect irreversible epithelial cell damage. No foot process
effacement or changes in epithelial cell endocytic function were
found despite the active endocytosis of filtered albumin. These
results are in sharp contrast with several earlier studies showing
that proteinuna causes irreversible structural and functional
abnormalities in glomerular epithelial cells [84, 85, 102—104].
This discrepancy has several possible explanations. One is a
different response of epithelial cells to protein load that can be
maximal early in the course of a given disease, when glomerular
ultrafiltrate contains large amount of proteins, and then adjusts
in such a way that further increases in filtered proteins are
associated with only minor and reversible changes. Since
epithelial cell changes have been studied only very early in a
given proteinuric condition [101], it is not surprising that studies
made later in the course of the diseases gave different results.
Efforts have also been made to clarify the possible relation-
ship between epithelial cell damage and the subsequent devel-
opment of glomerulosclerosis. It has been proposed that pro-
tein-induced injury to the epithelial cell inhibits the release of
heparin-like factor(s) that also have growth inhibiting effect and
control the abnormal proliferation of mesangial cells after
inflammatory, toxic or immunological stimuli [105—107]. More-
over, glomerular epithelial cells, in contrast to endothelial and
mesangial ones, do not replicate in response to proliferative
stimuli, so that when the glomerular tuft is enlarged—as in some
disease processes—only part of the glomerular surface area is
covered by hypertrophic podocytes [108—110]. This further
contributes to foot process distortion and detachment, further
increasing the traffic of macromolecules across the glomerular
capillary, given the reduced resistance to convective flow at the
extracellular filtration level [1]. Thus, large proteins are trapped
by the lamina densa of the GBM, expanding the subendothelial
space and promoting the accumulation of hyalin material [1].
Whether accumulation of this material stimulates endothelial
cells to produce mesangial matrix components, thus favoring
the process of focal glomerulosclerosis in a given glomerulus, is
for the time being still a matter for speculation. A recent
interesting line of research in this area has attributed to hyper-
throphy of remnant glomeruli, which developed in the remnant
kidney four to six weeks after nephrectomy, a specific role as
the determinant of subsequent glomerulosclerosis [5, 110, 111].
Since early hemodynamic pattern does not appear to correlate
with subsequent glomerular size in these studies, it has been
suggested that enhanced pressure and flow may not be the main
determinants of subsequent glomerulosclerosis. Since DNA
synthesis preceded increase in GFR [112], the possibility that a
circulating hormonal factor is responsible for glomerular hyper-
trophy has been proposed. Among the heterogeneity of glomer-
ular population a significant positive correlation has been found
by Yoshida et al [113] between glomerular size and the degree
of glomeruloscierosis. Glomerulosclerosis was attenuated in the
above-mentioned study both by enalapril as well as by other
antihypertensive therapies. Unfortunately no values of urinary
protein excretion are given, but since it has been extensively
documented that in remnant kidney as well as in other models
enalapnl has a marked antiproteinuric effect, the possibility that
proteinuria mediates the process of glomerulosclerosis which
predictably follows the process of remnant glomerular hyper-
trophy cannot be ruled out. Finally the observation that intact
nephrons are the primary origin of proteinuna in subtotal
nephrectomy [114], while severely damaged glomeruli contrib-
ute little to proteinuria, is consistent with the possibility that
proteinuria precedes and possibly triggers the development of
glomerular structural changes.
Tubulointerstitial damage
In most models of glomerulosclerosis, as well as in the
majority of human diseases, the progression of proteinuric
conditions to glomerulosclerosis is associated with interstitial
infiltration of inflammatory cells, particularly macrophages and
lymphocytes [61, 64, 65, 67, 75, 115, 116]. When the sequence
of events was monitored by repeated biopsies, as in two of our
recent studies on ADR nephrosis and in aging rats [61, 78], it
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was documented that interstitial damage preceded the develop-
ment of sclerotic lesions, thus suggesting a cause and effect type
of relationship. Similarly, in another model of proteinuria in
spontaneously hypertensive rats the extent of glomerulosclero-
sis was correlated with tubulointerstitial damage [118]. Tubu-
lointerstitial changes have been recognized many years ago in
progressive glomerulonephritis but so far have been regarded as
an "epiphenomenon" of glomerular sclerotic lesions. Several
recent observations may offer a new tool as for the possible
significance of such changes. Thus, serial biopsies performed in
aging rats and rats with ADR nephropathy indicated that the
massive entry of proteins into the urinary space results in
intense protein reabsorption activity of proximal tubular cells,
indicated by many reabsorption droplets in the cytoplasm of
proximal tubular epithelial cells [61, 78]. This event is in turn
followed by the formation of proteinaceous casts at distal points
that cause tubular dilatation and obstruction. In consequence of
dilatation and increased tubular pressure, tubular basement
membranes undergo focal breaks allowing the extravasation of
Tamm-Horsfall proteins into the interstitium [78]. Evidence of
loss of tubular basement membrane integrity derives from light
microscopy examination and from the finding that proteins
derived from the urinary space are accumulated in abnormal
amount in the interstitium [78]. This may be the trigger for the
interstitial inflammatory reaction which in most models pre-
cedes and possibly favors the development of glomerular scle-
rotic changes. Recently Davies et al [119] have shown that
Tamm-Horsfall glycoprotein interacts with human polymorpho-
nuclear leucocytes in vitro, activating the respiratory burst and
cell degranulation. If confirmed in vivo such an interaction
would offer an explanation for the findings of interstitial inflam-
mating reaction seen in association with Tamm-Horsfall pro-
tein. Unfortunately only few studies have addressed the cellular
characteristics of the interstitial inflammatory reactions. Eddy
and Michael [120] in chronic PA and ADR nephrosis found that
the cellular composition of the infiltrates was mainly macro-
phages and T-lymphocytes, the majority of which appear to be
T cytotoxic/suppressor cells. In other experimental models as
well (that is, reduction of renal mass and aging) infiltrating cells
into the interstitium had morphological characteristics of lym-
phocytes and macrophages [61, 65]. Of interest is that in aging
rats mononuclear cell infiltrates were seen in close contact with
sclerotic areas of the glomeruli, and inflammatory cells ap-
peared to penetrate the Bowman's capsule through breaks [61].
That proteinuria promotes tubular damage and interstitial
inflammation emerges quite clearly in the recent paper by Eddy
[121] in a model of overload proteinuria induced by repeated
injections of heterologous albumin in the rat. The study dem-
onstrates that after the onset of heavy proteinuria which follows
the administration of heterologous albumin, animals showed
tubular changes characterized by protein droplets in the cyto-
plasm of proximal tubular cells, casts and an early infiltration of
macrophages and then T lymphocytes in the interstitium. The
degree of inflammatory interstitial infiltration, which persisted
for the entire period of proteinuria, strictly correlated with the
amount of urinary proteins [121]. It has been proposed that
mononuclear cell infiltration represents the response to a tubu-
lar cell damage induced by proteinuria, possibly related to the
leakage of lysosomal enzymes in the cytoplasm of proximal
tubular cells as a consequence of an excessive amount of
readsorbed proteins. Based on the potential of inflammatory
cells to release biologically active mediators of tissue injury,
recent data may be taken as to indicate that lympho-monocytes
and macrophages surrounding the glomerular tuft have a poten-
tially critical role in modulating the activity of resident renal
cells and particularly mesangial cells. Thus macrophage-de-
rived products may stimulate the proliferation of mesangial
cells, the synthesis of extracellular matrix, and particularly
collagen, which may directly contribute to the process of
glomerulosclerosis [122—125]. Besides stimulating mesangial
cells to proliferate, macrophage-derived factors stimulate endo-
thelial cells to release inflammatory mediators, including inter-
leukin 1 (IL-l), that promotes the adherence of monocytes to
endothelium and stimulates the thromboxane A2 (TXA2) release
from platelets and possibly immune cells [126]. Interleukin 1
also induces platelet activating factor synthesis from either
endothelial or mesangial cells and increases the procoagulant
activity of resident glomerular cells [127]. All these are potential
stimuli for platelets to release platelet-derived factors among
which according to recent studies, platelet derived growth
factor (PDGF), transforming growth factor f3(TGF,3) and TxA2
may contribute to the process of mesangial proliferation, extra-
cellular matrix production and glomerular sclerosis [128—130].
In particular in vitro studies have documented that PDGF binds
to specific receptors on cultured human mesangial cells and
stimulates DNA synthesis and cell proliferation [128]. Whether
this mechanism is responsible for the glomerular hypertrophy
discussed above is still speculative. The fact that human mesan-
gial cells express mRNA for both A and B chains of PDGF and
secrete a PDGF-like protein would suggest that PGDF may
perhaps act as an autocrine and paracrine growth factor for
these cells [128]. Recent data have indicated that another
platelet-derived protein, TGF,3, stimulates extracellular matrix
production and regulates the structure of matrix proteoglycans
in cultured rat mesangial cells [129]. It is rather interesting to
note that TGF,3 appears to be unique in this property of inducing
glomerular extracellular matrix synthesis and does not share
this property with other growth factors, like IL-l, PGDF or
TNF. Since TGF is released by inflammatory cells, it is
conceivable that it plays a role in glomerulonephritis and
possibly participates in the process of glomerular obsolescence.
Finally a recent study has documented that TxA2 has a direct
effect on the biosynthesis of extracellular matrix proteins in-
ducing a dose-dependent increase in laminin A, B and B2 chains
[130]. This raises the question whether TxA2, which is released
from activated platelets and macrophages during inflammatory
reactions, is directly linked to the development of glomerulo-
sclerosis and interstitial fibrosis.
Summary
Numerous studies in the last decade have set out to clarify
the process of progressive deterioration of renal function that
occurs in animals and humans after a critical reduction in the
number of nephron units either by surgical ablation or by
various diseases. Most of these studies were stimulated by
Brenner, Meyer and Hostetter's provocative review on "Di-
etary protein intake and the progressive nature of kidney
disease" published in the New England Journal of Medicine in
1982 [2]. This view focused for the first time on the possibility
of a common hemodynamic pathway responsible for the pro-
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gression of renal disease independent of the initial injury.
According to Brenner's group hypothesis, the fundamental
lesion responsible for progressive renal insufficiency was scle-
rosis of the glomerular capillary tuft resulting from sustained
elevation of glomerular pressures and flows in remnant glomer-
uli after the loss of a critical number of functioning nephrons.
Most of the subsequent studies followed this original interpre-
tation. However, since measurement of glomerular capillary
pressure did not produce uniform results in the various models
[67, 68, 791, some of them challenged the hypothesis of hemo-
dynamically-mediated glomerular injury suggesting alternative
mechanisms. Thus disorders of lipid metabolism [4], activation
of coagulation and intraglomerular thrombosis [3], intrarenal
calcium deposits [131] and glomerular hypertrophy [5], all have
been claimed as key determinant for glomerulosclerosis. In-
deed, in some models correction of these abnormalities pre-
vented renal disease progression [113, 132—135]. However,
none of these studies convincingly clarified the issue of a
common determinant of renal disease progression. This review
offers an integrated interpretation of renal disease progression,
at least in rat models. We have documented that glomerular
obsolescence induced by surgery, aging or some toxins share a
sustained abnormality in glomerular permeability to macromol-
ecules that is long lasting and can be regarded as the common
determinant of glomerulosclerosis more than as a consequence
of glomerular injury. There are at least two pathways of
disruption of glomerular permselectivity in rat models of gb-
merulosclerosis (Fig. 1). One is through increased glomerular
capillary pressures which determine a mechanical injury to the
glomerular capillary barrier and operate for instance in remnant
kidney or experimental diabetes [6, 7, 22, 23]. The other is
initiated by toxins or immune reactants that may alter glomer-
ular permselectivity even in the absence of increased glomeru-
lar capillary pressure [67, 79]. Once glomerular permselectivity
has been disrupted, the disease progresses to end-stage renal
failure by a process triggered by the exposure of renal cells to
the abnormal protein load which does not depend on the initial
injury. Thus, mesangial cells exposed to an abnormal protein
traffic may proliferate and synthesize mesangial matrix in
excessive amounts [96, 97]. Similarly, glomerular epithelial
cells undergo structural and functional modifications, including
focal detachment from basement membrane, with further in-
crease of the passage of macromolecules across the glomerular
capillaries [1]. This results in an increased amount of proteins in
the ultrafiltrate that overwhelms proximal tubular epithelial cell
reabsorption capacity [78]. The abnormal amount of proteins
delivered to distal tubuli leads to the formation of casts breaking













Fig. 1. Mechanisms by which alterations in
glomerular selective properties may lead to
glomerulosclerosis as a result of modifications
in inesangial, epithelial or tubular cell
function, This scheme applies both to renal
diseases with normal or increased
intraglomerular capillary pressure.
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inflammatory reaction [78]. Inflammatory cells surrounding the
glomeruli that subsequently become sclerotic very probably
play a major role in this process [61, 78]. They may do so by
releasing factors that can—as has been recently documented—
induce mesangial cell proliferation and promote abnormal gen-
eration of mesangial matrix [128—130]. If this interpretation is
correct, maneuvers that limit abnormalities in glomerular cap-
illary permeability will have a pivotal role in retarding renal
disease progression, at least in experimental models. Whether
these concepts apply to human renal disease progression is a
possibility that merits appropriate investigation. With appropri-
ate experiments the question of whether glomerulosclerosis is a
consequence of alterations in membrane permselective proper-
ties may hopefully have a definitive answer in the near future, at
least in animals. The most promising model appears the model
of spontaneous glomeruloscierosis occurring in male MWF/
ztm. The possibility to reduce both proteinuria and glomerulo-
sclerosis with enalapril in such a model, which is devoid of
glomerular capillary hypertension, represents a powerful inves-
tigative tool [621. One can design experiments with different
doses of enalapril in order to modulate urinary protein excretion
values from very high to normal with some intermediate targets.
Should this maneuver result in a varying degree of glomerular
sclerotic lesion from 30% to almost zero with intermediate
values consistent with the levels of urinary protein excretion,
this would certainly contribute to validate the present hypoth-
esis.
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